hesitancy, people in the population that we re talking about if, there are a four booster vaccine will probably take it. but it does now cause people to pause, if i got one johnson & johnson and they re going to approve a second one is a booster. do i do that, or i d try to wait to figure out if i should just take a pfizer or moderna shot? i think they picture that you are still very well protected. i ve got this very same question from people i know who ve gotten a single johnson & johnson, should i go ahead and get that j&j or should i wait? i think unless you re in a place where there s lots of transmission. where you are in a high-risk occupation, you can afford to wait a couple more weeks here well we sort out which is the second dose of vaccine, is it j&j, is it pfizer, is moderna. what do you think of the implied criticism by some members of the panel, that maybe this should have been a two dose shot in the first place? i think it was really noble to try to have a single d
or pfizer one? the panel heard some groundbreaking data from the nih on that exact question, the studies show that people who got initial shot of johnson & johnson, saw the biggest immune response when they got a moderna booster shot, of pfizer booster shot was second best providing a big jump in antibody levels, but a second shot of johnson & johnson vaccine resulted in the lowest increase in antibody levels. the panel did not vote today on whether or not to recommend mixing and matching vaccines and booster brands, but it seems like that might be on the horizon. when it comes to johnson & johnson boosters at large, the fda panel today, voted unanimously, 19 to 0 to recommend those boosters, essentially saying that their public health imperative since the immune response to the primary johnson & johnson vaccine is so low compared to moderna and pfizer. one panel member, echoed the feelings of several of his colleagues when he said quote, i think this frankly was always
kids. lawrence jones says if you have children, you get to stay. yes. absolutely. ainsley: thank you, tom. brian: tom, great reporting. no one has that information. ainsley: 7:30 on the east coast. american residence still strapped over there in afghanistan as they are hiding from the taliban. groups like the task force pineapple are working nonstop to go and get them and bring them home. the leader of that group scott mann gives an update on that mission. steve: it pfizer announces a small deals of their vaccine is good for kids. are parents ready to get their kids vaccinated? a parent panel on that coming up next. my patients are able to have that quality of life back. i recommend sensodyne repair and protect with deep repair.
appropriate efficacy in children with a dose and a vaccine that s going to be hopefully much more tolerable given reluctance of some parents to use a vaccine in children. so hopefully if you have a more tolerable vaccine that s going to inspire more people to feel comfortable using t pfizer will be in a position to file with the fda within a matter of days, the data package from this clinical trial, the fda has said that the review is going to be a matter of weeks, not months. i interpret that to suggest that the agency is likely to take four to six weeks to review this application. so on the good end, you could see an authorization perhaps by the end of october, by halloween. if it slips a couple weeks, maybe by mid-november, but if the fda s review goes well, if they affirm the integrity of the data that pfizer is submitting to the agency and they ultimately judge this to be safe and effective for children, you could see an authorization as early as a month for children ages 5 to 11.
under an emergency use authorization initially, as will the boosters. it s going to also be under an emergency use authorization at least initially. this is a vaccine for children ages 5 to 11, it s a smaller dose than the dose used in the adult population. the exact same vaccine but one-tenth the dose so a smaller dose one-third the dose, excuse me. the reason is that pfizer tested different doses and tried to find the dose that provides the optimal amount of protection in terms of antibody response. so this dose in children ages 5 to 11 provides a comparable level of antibodies response to the dose that we used in children ages 16 to 25. so we compared it to kids ages 16 to 25, it actually produces slightly more antibodies but because it s a lower dose the hope is that it s going to be less reactive genicity, less vaccine related side effects like fevers and injection-site reactions and provide a greater margin of safety. safety really was the focus in terms of trying to find the d